绿康生化(002868) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥90,930,335.34, representing a 10.21% increase compared to ¥82,505,391.38 in the same period last year[8] - Net profit attributable to shareholders decreased by 81.80% to ¥2,401,830.67 from ¥13,195,905.25 year-on-year[8] - Operating profit decreased by 90.48% to CNY 1,509,334.75 compared to CNY 15,855,120.01 in the same period last year[19] - Net profit for the current period was ¥7,189,068.19, down from ¥13,071,900.69 in the previous period, representing a decrease of 45.0%[59] - Total profit for the current period was ¥7,540,604.56, down from ¥15,321,272.00, a decrease of 50.9%[58] - Basic earnings per share for the current period were ¥0.050, compared to ¥0.11 in the previous period, a decrease of 54.5%[59] Cash Flow - The net cash flow from operating activities was negative at -¥25,012,216.19, a decline of 285.85% compared to ¥13,458,368.76 in the previous year[8] - The net cash flow from operating activities was -19,837,279.99, a decrease compared to 12,495,721.77 in the previous period[66] - Cash inflow from operating activities totaled 66,814,777.53, a decline from 89,707,822.13 in the previous period[66] - The company reported a net cash flow from investing activities of -73,556,187.37, compared to -7,810,536.97 in the previous period[66] - The net cash flow from financing activities was 27,439,799.29, compared to -26,947,198.95 in the previous period[67] Assets and Liabilities - The total assets at the end of the reporting period increased by 2.87% to ¥1,000,367,117.05 from ¥972,502,779.28 at the end of the previous year[8] - Total assets as of March 31, 2021, reached CNY 973,621,731.25, compared to CNY 944,584,726.17 at the end of 2020[48] - Total liabilities increased to CNY 229,145,939.03 from CNY 202,559,099.70 year-over-year[46] - The total assets as of the end of the period were 972,502,779.28, with total liabilities of 202,559,099.70[70] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,620[12] - The top shareholder, Shanghai Kangyi Investment Co., Ltd., held 30.43% of the shares, amounting to 47,291,400 shares[13] - The company repurchased 2,011,507 shares, accounting for 1.29% of total shares, with a total expenditure of CNY 32,406,447.45[27] Research and Development - R&D expenses increased by 67.40% to CNY 6,280,220.20, primarily due to higher depreciation and outsourced technical service costs[19] - Research and development expenses increased to CNY 6,280,220.20, a rise of 67.4% from CNY 3,751,575.06 in the previous year[52] - The company has invested ¥20.46 million in the project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials (sulfamethoxazole) as of March 31, 2021[31] Borrowings and Financial Expenses - Short-term borrowings surged by 761.95% to ¥43,143,125.10, primarily due to new bank loans taken during the period[18] - Financial expenses increased by 43.32% to CNY -629,813.90, mainly due to exchange rate fluctuations[19] - Long-term borrowings decreased to CNY 52,000,000.00 from CNY 57,000,000.00 year-over-year[46] Other Income and Expenses - The company recorded non-operating income of ¥1,740,532.87 from government subsidies during the reporting period[10] - Other income rose by 146.42% to CNY 1,740,905.27, mainly due to increased government subsidies[19] - The company incurred asset impairment losses of -¥1,448,226.23, compared to -¥640,868.27 in the previous period, indicating an increase in losses[58] Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose by 90.49% to ¥58,039,389.21 due to increased sales in March[18] - Accounts receivable increased significantly to ¥58.04 million from ¥30.47 million, marking an increase of approximately 90.5%[42] - The company reported a significant increase in accounts receivable, which rose to CNY 49,316,976.91 from CNY 26,849,403.09 in the previous year[46] Project Updates - The project for the technical center expansion was completed and accepted by April 2020, with surplus funds of ¥50 million allocated to supplement working capital[32] - The company has postponed the completion date of the active bacterial peptide project to September 30, 2021, due to delays caused by the COVID-19 pandemic[31] Compliance and Audit - The company has not undergone an audit for the first quarter report[74] - The report indicates that the company has not applied the new leasing standards retrospectively[73]